Evidence-based pharmacotherapy of obsessive-compulsive disorder - PubMed

Affiliations

• PMID: 22226028
• DOI: 10.1017/S1461145711001829

Free article

Review

Evidence-based pharmacotherapy of obsessive-compulsive disorder

Naomi A Fineberg et al. Int J Neuropsychopharmacol. 2012 Sep.

Free article

Abstract

Pharmacological strategies for the treatment of obsessive-compulsive disorder (OCD) continue to develop apace but deficiencies remain. We present an updated literature review of the evidence supporting available strategies. We aim to answer key questions including: (1) What are the first-line treatments? (2) Does pharmacotherapy improve health-related quality of life? (3) How do we evaluate clinical response and relapse? (4) How long should treatment continue? (5) Can we predict treatment outcomes? (6) What is the management of treatment-refractory OCD? Selective serotonin reuptake inhibitors (SSRIs) remain the pharmacological treatment of choice for most patients and are associated with improved health-related quality of life. However, discontinuation is associated with relapse and loss of quality of life, implying treatment should continue long term. A substantial minority of patients fail to respond to SSRI. Such patients may respond to strategies such as dose elevation or adjunctive antipsychotic, although long-term trials validating the effectiveness and tolerability of these strategies are relatively lacking. Newer compounds targeting other neurotransmitter systems, such as glutamate, are undergoing evaluation.

Similar articles

• Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.

  Fineberg NA, Reghunandanan S, Brown A, Pampaloni I. Fineberg NA, et al. Aust N Z J Psychiatry. 2013 Feb;47(2):121-41. doi: 10.1177/0004867412461958. Epub 2012 Nov 2. Aust N Z J Psychiatry. 2013. PMID: 23125399 Review.

• Evidence-based pharmacotherapy of obsessive-compulsive disorder.

  Fineberg NA, Gale TM. Fineberg NA, et al. Int J Neuropsychopharmacol. 2005 Mar;8(1):107-29. doi: 10.1017/S1461145704004675. Epub 2004 Sep 28. Int J Neuropsychopharmacol. 2005. PMID: 15450126 Review.

• A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.

  Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G. Albert U, et al. Curr Med Chem. 2018;25(41):5647-5661. doi: 10.2174/0929867325666171222163645. Curr Med Chem. 2018. PMID: 29278206

• Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.

  Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Issari Y, et al. J Clin Psychiatry. 2016 May;77(5):e605-11. doi: 10.4088/JCP.14r09758. J Clin Psychiatry. 2016. PMID: 27249090

• Pharmacotherapy for obsessive-compulsive disorder.

  Greist JH, Jefferson JW. Greist JH, et al. Br J Psychiatry Suppl. 1998;(35):64-70. Br J Psychiatry Suppl. 1998. PMID: 9829028 Review.

Cited by

• Brain serotonin signaling does not determine sexual preference in male mice.

  Angoa-Pérez M, Herrera-Mundo N, Kane MJ, Sykes CE, Anneken JH, Francescutti DM, Kuhn DM. Angoa-Pérez M, et al. PLoS One. 2015 Feb 23;10(2):e0118603. doi: 10.1371/journal.pone.0118603. eCollection 2015. PLoS One. 2015. PMID: 25706994 Free PMC article.

• Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.

  Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA, Salkovskis P, Welton NJ, Baxter H, Kessler D, Churchill R, Lewis G. Skapinakis P, et al. Lancet Psychiatry. 2016 Aug;3(8):730-739. doi: 10.1016/S2215-0366(16)30069-4. Epub 2016 Jun 16. Lancet Psychiatry. 2016. PMID: 27318812 Free PMC article. Review.

• Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial.

  Khalkhali M, Aram S, Zarrabi H, Kafie M, Heidarzadeh A. Khalkhali M, et al. Iran J Psychiatry. 2016 Apr;11(2):104-14. Iran J Psychiatry. 2016. PMID: 27437007 Free PMC article.

• Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming.

  Brownstien M, Lazar M, Botvinnik A, Shevakh C, Blakolmer K, Lerer L, Lifschytz T, Lerer B. Brownstien M, et al. Mol Psychiatry. 2025 Mar;30(3):1172-1183. doi: 10.1038/s41380-024-02786-0. Epub 2024 Oct 11. Mol Psychiatry. 2025. PMID: 39394457 Free PMC article.

• Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial.

  Shannahoff-Khalsa D, Fernandes RY, Pereira CAB, March JS, Leckman JF, Golshan S, Vieira MSR, Polanczyk GV, Miguel EC, Shavitt RG. Shannahoff-Khalsa D, et al. Front Psychiatry. 2019 Nov 11;10:793. doi: 10.3389/fpsyt.2019.00793. eCollection 2019. Front Psychiatry. 2019. PMID: 31780963 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information